[시장보고서]세계의 원료의약품용 CDMO 시장 규모, 점유율, 동향 분석 : 제품별, 합성별, 약제별, 용도별, 워크플로우별, 지역별, 부문별 예측(2025-2033년)

세계의 원료의약품용 CDMO 시장 규모, 점유율, 동향 분석 : 제품별, 합성별, 약제별, 용도별, 워크플로우별, 지역별, 부문별 예측(2025-2033년)

Active Pharmaceutical Ingredient CDMO Market Size, Share & Trends Analysis Report By Product By Synthesis, By Drug, By Application, By Workflow, By Region, And Segment Forecasts, 2025 - 2033

상품코드 : 1841981

리서치사 : Grand View Research

발행일 : 2025년 09월

페이지 정보 : 영문 150 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,704,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 10,167,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 13,093,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

원료의약품용 CDMO 시장 요약

세계의 원료의약품용 CDMO 시장 규모는 2024년에 1,072억 1,000만 달러로 추계되며, 2033년에는 2,098억 5,000만 달러에 달할 것으로 예측되며, 2025-2033년 CAGR은 7.85%로 성장할 것으로 예측됩니다.

확장 가능하고 비용 효율적인 의약품 개발 솔루션에 대한 수요 증가, 운영 비용을 절감하고 핵심 역량에 집중하기 위한 제약사의 아웃소싱 증가, 특수하고 복잡한 원료의약품에 대한 연구개발 활동의 활성화 등이 시장을 주도하고 있습니다.

또한 바이오시밀러 및 바이오의약품 분야의 성장, 만성질환 증가, 블록버스터 의약품의 특허만료, 연속생산 및 고역가 원료의약품 등 제조기술의 발전이 산업 성장에 더욱 기여하고 있습니다. 또한 제약사 및 바이오테크 기업이 CDMO에 원료의약품 제조 서비스를 위탁하는 사례가 증가하고 있으며, 이는 시장 성장의 주요 요인 중 하나입니다. 의약품 분자의 복잡성과 CDMO가 제공하는 비용 이점이 사내 역량에서 아웃소싱으로 전환하는 주요 요인으로 작용하고 있습니다. 또한 전 세계에서 만성질환이 증가함에 따라 혁신적인 치료법에 대한 수요가 증가함에 따라 CDMO는 대규모 생산, 개발 가속화, 규제 준수에 집중하고 있습니다.

또한 생물제제와 바이오시밀러 파이프라인 증가와 HPAPI에 대한 수요가 증가하고 있는 것도 기회 증가에 기여하고 있습니다. CDMO는 첨단 전문성과 첨단 기술을 보유하고 있으며, 확장 가능하고 컴플라이언스를 준수하며 효율적인 제조 솔루션을 원하는 바이오테크놀러지 및 제약회사들에게 선호되는 선택이 되고 있습니다. 또한 오리지널 의약품과 블록버스터 의약품의 특허 만료로 인해 제네릭 원료의약품에 대한 수요가 증가하고 있습니다. 이러한 요인들은 시장 경쟁 구도를 변화시키고 시장 성장에 더욱 기여하고 있습니다.

시장 대시보드 : 지역별
세계 시장 스냅숏 : 지역별
시장 규모 예측과 동향 분석(2021-2033년)
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트
- 오만
- 카타르

제10장 경쟁 구도

기업 분류
- 시장 리더
- 신규 기업
원료의약품용 CDMO 시장 점유율 분석(2024년)
기업 개요
- Cambrex Corporation
- Recipharm AB
- Thermo Fisher Scientific Inc.
- CordenPharma International
- Samsung Biologics
- Lonza
- Catalent, Inc.
- Siegfried Holding AG
- Piramal Pharma Solutions
- Boehringer Ingelheim International GmbH

KSA

영문 목차

영문목차

Active Pharmaceutical Ingredient CDMO Market Summary

The global active pharmaceutical ingredient CDMO market size was estimated at USD 107.21 billion in 2024 and is projected to reach USD 209.85 billion by 2033, growing at a CAGR of 7.85% from 2025 to 2033. The market is driven due to the increasing demand for scalable and cost-efficient drug development solutions, growing outsourcing trends among pharmaceutical companies to reduce operational costs and focus on core competencies, and increasing R&D activities in specialty and complex APIs.

Moreover, the growing biosimilars and biologics segment, increasing prevalence of chronic diseases, patent expirations of blockbuster drugs, and advancements in manufacturing technologies such as continuous manufacturing and high-potency APIs are further contributing to the industry growth. In addition, several pharmaceutical and biotechnology companies are increasingly outsourcing their API manufacturing services to CDMOs, which is also one of the major factors contributing to market growth. The increasing complexity of drug molecules and the cost advantages offered by CDMOs are the major contributors to the shift from in-house capabilities to outsourcing. Furthermore, the increasing prevalence of chronic diseases globally has intensified the demand for innovative therapies, further pushing the CDMOs to focus on large-scale production, faster development, and regulatory compliance.

Furthermore, increasing pipelines of biologics and biosimilars and a growing demand for HPAPIs contribute to the increasing opportunities. CDMOs have higher levels of expertise and advanced technologies, making them the preferred choice for biotechnology and pharmaceutical companies looking for scalable, compliant, and efficient manufacturing solutions. Moreover, patent expirations of branded and blockbuster drugs are boosting the demand for generic APIs. Thus, these factors are changing the market's competitive landscape, further contributing to the market growth.

Global Active Pharmaceutical Ingredient CDMO Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global active pharmaceutical ingredient CDMO market report based on product, synthesis, drug, application, workflow, and region:

Product Outlook (Revenue, USD Billion, 2021 - 2033)
Traditional Active Pharmaceutical Ingredient (Traditional API)
Highly Potent Active Pharmaceutical Ingredient (HP-API)
Biologics
Synthesis Outlook (Revenue, USD Billion, 2021 - 2033)
Synthetic
Biotech
Drug Outlook (Revenue, USD Billion, 2021 - 2033)
Innovative
Generics
Workflow Outlook (Revenue, USD Billion, 2021 - 2033)
Clinical
Commercial
Application Outlook (Revenue, USD Billion, 2021 - 2033)
Oncology
Hormonal
Glaucoma
Cardiovascular disease
Diabetes
Others
Regional Outlook (Revenue, USD Billion, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Norway
- Sweden
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
Latin America
- Brazil
- Argentina
Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
- Oman
- Qatar

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
1.5. Information or Data Analysis
- 1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Value chain based analysis (Model 2)
- 1.7.3. Multivariate Analysis (Model 3)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Landscape Insights

Chapter 3. Active Pharmaceutical Ingredient CDMO Market: Variables, Trends, & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Ancillary Market Outlook
3.2. Active Pharmaceutical Ingredient CDMO Market Dynamics
- 3.2.1. Market Driver Impact Analysis
- 3.2.2. Market Restraint Analysis
- 3.2.3. Market Opportunities
3.3. Technological Landscape
3.4. Pricing Model Analysis
3.5. Tariff Impact Analysis
3.6. Supply Chain Analysis
3.7. Market Analysis Tools
- 3.7.1. Porter's Five Forces Analysis
- 3.7.2. PESTEL by SWOT Analysis

Chapter 4. Active Pharmaceutical Ingredient CDMO Market: Product Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Global Active Pharmaceutical Ingredient CDMO Market Product Movement Analysis
4.3. Global Active Pharmaceutical Ingredient CDMO Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Billion)
4.4. Traditional Active Pharmaceutical Ingredient (Traditional API)
- 4.4.1. Traditional Active Pharmaceutical Ingredient (Traditional API) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
4.5. Highly Potent Active Pharmaceutical Ingredient (HP-API)
- 4.5.1. Highly Potent Active Pharmaceutical Ingredient (HP-API) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
4.6. Biologics
- 4.6.1. Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 5. Active Pharmaceutical Ingredient CDMO Market: Synthesis Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Global Active Pharmaceutical Ingredient CDMO Market Synthesis Movement Analysis
5.3. Global Active Pharmaceutical Ingredient CDMO Market Size & Trend Analysis, by Synthesis, 2021 to 2033 (USD Billion)
5.4. Synthetic
- 5.4.1. Synthetic Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
5.5. Biotech
- 5.5.1. Biotech Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 6. Active Pharmaceutical Ingredient CDMO Market: Drug Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Global Active Pharmaceutical Ingredient CDMO Market Drug Movement Analysis
6.3. Global Active Pharmaceutical Ingredient CDMO Market Size & Trend Analysis, by Drug, 2021 to 2033 (USD Billion)
6.4. Innovative
- 6.4.1. Innovative Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
6.5. Generics
- 6.5.1. Generics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 7. Active Pharmaceutical Ingredient CDMO Market: Application Estimates & Trend Analysis

7.1. Segment Dashboard
7.2. Global Active Pharmaceutical Ingredient CDMO Market Application Movement Analysis
7.3. Global Active Pharmaceutical Ingredient CDMO Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Billion)
7.4. Oncology
- 7.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.5. Hormonal
- 7.5.1. Hormonal Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.6. Glaucoma
- 7.6.1. Glaucoma Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.7. Cardiovascular disease
- 7.7.1. Cardiovascular disease Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.8. Diabetes
- 7.8.1. Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
7.9. Others
- 7.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 8. Active Pharmaceutical Ingredient CDMO Market: Workflow Estimates & Trend Analysis

8.1. Segment Dashboard
8.2. Global Active Pharmaceutical Ingredient CDMO Market Workflow Movement Analysis
8.3. Global Active Pharmaceutical Ingredient CDMO Market Size & Trend Analysis, by Workflow, 2021 to 2033 (USD Billion)
8.4. Clinical
- 8.4.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
8.5. Commercial
- 8.5.1. Commercial Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 9. Active Pharmaceutical Ingredient CDMO Market: Regional Estimates & Trend Analysis by Product, Synthesis, Drug, Application, Workflow

9.1. Regional Market Dashboard
9.2. Global Regional Market Snapshot
9.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
9.4. North America
- 9.4.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.4.2. U.S.
  - 9.4.2.1. Key Country Dynamics
  - 9.4.2.2. Competitive Scenario
  - 9.4.2.3. Regulatory Framework
  - 9.4.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.4.3. Canada
  - 9.4.3.1. Key Country Dynamics
  - 9.4.3.2. Competitive Scenario
  - 9.4.3.3. Regulatory Framework
  - 9.4.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.4.4. Mexico
  - 9.4.4.1. Key Country Dynamics
  - 9.4.4.2. Competitive Scenario
  - 9.4.4.3. Regulatory Framework
  - 9.4.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
9.5. Europe
- 9.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.5.2. UK
  - 9.5.2.1. Key Country Dynamics
  - 9.5.2.2. Competitive Scenario
  - 9.5.2.3. Regulatory Framework
  - 9.5.2.4. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.5.3. Germany
  - 9.5.3.1. Key Country Dynamics
  - 9.5.3.2. Competitive Scenario
  - 9.5.3.3. Regulatory Framework
  - 9.5.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.5.4. France
  - 9.5.4.1. Key Country Dynamics
  - 9.5.4.2. Competitive Scenario
  - 9.5.4.3. Regulatory Framework
  - 9.5.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.5.5. Italy
  - 9.5.5.1. Key Country Dynamics
  - 9.5.5.2. Competitive Scenario
  - 9.5.5.3. Regulatory Framework
  - 9.5.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.5.6. Spain
  - 9.5.6.1. Key Country Dynamics
  - 9.5.6.2. Competitive Scenario
  - 9.5.6.3. Regulatory Framework
  - 9.5.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.5.7. Denmark
  - 9.5.7.1. Key Country Dynamics
  - 9.5.7.2. Competitive Scenario
  - 9.5.7.3. Regulatory Framework
  - 9.5.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.5.8. Sweden
  - 9.5.8.1. Key Country Dynamics
  - 9.5.8.2. Competitive Scenario
  - 9.5.8.3. Regulatory Framework
  - 9.5.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.5.9. Norway
  - 9.5.9.1. Key Country Dynamics
  - 9.5.9.2. Competitive Scenario
  - 9.5.9.3. Regulatory Framework
  - 9.5.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
9.6. Asia Pacific
- 9.6.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.6.2. Japan
  - 9.6.2.1. Key Country Dynamics
  - 9.6.2.2. Competitive Scenario
  - 9.6.2.3. Regulatory Framework
  - 9.6.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.6.3. China
  - 9.6.3.1. Key Country Dynamics
  - 9.6.3.2. Competitive Scenario
  - 9.6.3.3. Regulatory Framework
  - 9.6.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.6.4. India
  - 9.6.4.1. Key Country Dynamics
  - 9.6.4.2. Competitive Scenario
  - 9.6.4.3. Regulatory Framework
  - 9.6.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.6.5. Australia
  - 9.6.5.1. Key Country Dynamics
  - 9.6.5.2. Competitive Scenario
  - 9.6.5.3. Regulatory Framework
  - 9.6.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.6.6. South Korea
  - 9.6.6.1. Key Country Dynamics
  - 9.6.6.2. Competitive Scenario
  - 9.6.6.3. Regulatory Framework
  - 9.6.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.6.7. Thailand
  - 9.6.7.1. Key Country Dynamics
  - 9.6.7.2. Competitive Scenario
  - 9.6.7.3. Regulatory Framework
  - 9.6.7.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
9.7. Latin America
- 9.7.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.7.2. Brazil
  - 9.7.2.1. Key Country Dynamics
  - 9.7.2.2. Competitive Scenario
  - 9.7.2.3. Regulatory Framework
  - 9.7.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.7.3. Argentina
  - 9.7.3.1. Key Country Dynamics
  - 9.7.3.2. Competitive Scenario
  - 9.7.3.3. Regulatory Framework
  - 9.7.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
9.8. MEA
- 9.8.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.8.2. South Africa
  - 9.8.2.1. Key Country Dynamics
  - 9.8.2.2. Competitive Scenario
  - 9.8.2.3. Regulatory Framework
  - 9.8.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.8.3. Saudi Arabia
  - 9.8.3.1. Key Country Dynamics
  - 9.8.3.2. Competitive Scenario
  - 9.8.3.3. Regulatory Framework
  - 9.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.8.4. UAE
  - 9.8.4.1. Key Country Dynamics
  - 9.8.4.2. Competitive Scenario
  - 9.8.4.3. Regulatory Framework
  - 9.8.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.8.5. Kuwait
  - 9.8.5.1. Key Country Dynamics
  - 9.8.5.2. Competitive Scenario
  - 9.8.5.3. Regulatory Framework
  - 9.8.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.8.6. Oman
  - 9.8.6.1. Key Country Dynamics
  - 9.8.6.2. Competitive Scenario
  - 9.8.6.3. Regulatory Framework
  - 9.8.6.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.8.7. Qatar
  - 9.8.7.1. Key Country Dynamics
  - 9.8.7.2. Competitive Scenario
  - 9.8.7.3. Regulatory Framework
  - 9.8.7.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 10. Competitive Landscape

10.1. Company Categorization
- 10.1.1. Market Leaders
- 10.1.2. Emerging Players
10.2. Active Pharmaceutical Ingredient CDMO Market Share Analysis, 2024
10.3. Company Profiles
- 10.3.1. Cambrex Corporation
  - 10.3.1.1. Company Overview
  - 10.3.1.2. Financial Performance
  - 10.3.1.3. Product/Service Benchmarking
  - 10.3.1.4. Strategic Initiatives
- 10.3.2. Recipharm AB
  - 10.3.2.1. Company Overview
  - 10.3.2.2. Financial Performance
  - 10.3.2.3. Product/Service Benchmarking
  - 10.3.2.4. Strategic Initiatives
- 10.3.3. Thermo Fisher Scientific Inc.
  - 10.3.3.1. Company Overview
  - 10.3.3.2. Financial Performance
  - 10.3.3.3. Product/Service Benchmarking
  - 10.3.3.4. Strategic Initiatives
- 10.3.4. CordenPharma International
  - 10.3.4.1. Company Overview
  - 10.3.4.2. Financial Performance
  - 10.3.4.3. Product/Service Benchmarking
  - 10.3.4.4. Strategic Initiatives
- 10.3.5. Samsung Biologics
  - 10.3.5.1. Company Overview
  - 10.3.5.2. Financial Performance
  - 10.3.5.3. Product/Service Benchmarking
  - 10.3.5.4. Strategic Initiatives
- 10.3.6. Lonza
  - 10.3.6.1. Company Overview
  - 10.3.6.2. Financial Performance
  - 10.3.6.3. Product/Service Benchmarking
  - 10.3.6.4. Strategic Initiatives
- 10.3.7. Catalent, Inc.
  - 10.3.7.1. Company Overview
  - 10.3.7.2. Financial Performance
  - 10.3.7.3. Product/Service Benchmarking
  - 10.3.7.4. Strategic Initiatives
- 10.3.8. Siegfried Holding AG
  - 10.3.8.1. Company Overview
  - 10.3.8.2. Financial Performance
  - 10.3.8.3. Product/Service Benchmarking
  - 10.3.8.4. Strategic Initiatives
- 10.3.9. Piramal Pharma Solutions
  - 10.3.9.1. Company Overview
  - 10.3.9.2. Financial Performance
  - 10.3.9.3. Product/Service Benchmarking
  - 10.3.9.4. Strategic Initiatives
- 10.3.10. Boehringer Ingelheim International GmbH
  - 10.3.10.1. Company Overview
  - 10.3.10.2. Financial Performance
  - 10.3.10.3. Product/Service Benchmarking
  - 10.3.10.4. Strategic Initiatives

한글목차

원료의약품용 CDMO 시장 요약

목차

제1장 분석 방법·범위

제2장 개요

제3장 원료의약품용 CDMO 시장 : 변동 요인·동향·범위

제4장 원료의약품용 CDMO 시장 : 제품별 추정·동향 분석

제5장 원료의약품용 CDMO 시장 : 합성별 추정·동향 분석

제6장 원료의약품용 CDMO 시장 : 약제별 추정·동향 분석

제7장 원료의약품용 CDMO 시장 : 용도별 추정·동향 분석

제8장 원료의약품용 CDMO 시장 : 워크플로우별 추정·동향 분석

제9장 원료의약품용 CDMO 시장 : 지역별 추정·동향 분석(제품별, 합성별, 약제별, 용도별, 워크플로우별)